A new study helps explain why having ApoE4—the gene variant most closely linked to Alzheimer's disease—increases the risk of ...
The ALPS index effectively distinguishes individuals with SCD from those with normal cognition and is correlated with amyloid beta burden.
The plaque building is one component of Alzheimer's disease pathology, the release said. A hallmark of Alzheimer's is the ...
A characteristic feature of this condition is the build-up of beta-amyloid protein in the brain, which is connected to tissue ...
A study published Wednesday in Nature Neuroscience sheds light into how amyloid-beta and tau proteins impact brain activity ...
Despite enormous effort, disease-modifying therapies for Alzheimer's disease, the most common cause of dementia, have proven ...
aDementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, UK bDepartment of Clinical and Movement Neurosciences, Queen Square Brain Bank for Neurological ...
The FDA’s approval of Kisunla demonstrates a positive change in Alzheimer disease management. Offering illness pathology therapy and the option of treatment conclusion after reaching therapeutic goals ...
New research suggests that the lessening of amyloid-beta in the brain is behind cognitive decline in Alzheimer's and boosting ...
The scientists looked at two brain scans and found that areas with more amyloid-beta showed increased brain activity, with ...
GlobalData on MSN1d
GE HealthCare’s MIM Software scoops FDA clearance on Alzheimer’s diagnosticMIM Software has secured 510(k) clearance from the US Food and Drug Administration (FDA) to offer its MIMneuro software with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback